{"id":60595,"date":"2024-10-16T12:04:45","date_gmt":"2024-10-16T12:04:45","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/16\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/"},"modified":"2024-10-16T12:04:45","modified_gmt":"2024-10-16T12:04:45","slug":"igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/","title":{"rendered":"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer"},"content":{"rendered":"<div>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HONG KONG<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 16, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Akeso Biopharma (9926.HK)\u00a0 (&#8221; Akeso&#8221;, the &#8220;Company&#8221; ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16\/AK104-303). This study evaluated the efficacy of its independently developed PD-1\/CTLA-4 bispecific antibody, \u5f00\u5766\u5c3c\u00ae (cadonilimab), in combination with or without platinum-based chemotherapy and bevacizumab, compared to placebo with platinum-based chemotherapy and bevacizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer. These findings were presented as a Late-Breaking Abstract (LBA) in an oral session at the 2024 annual global meeting of the International Gynecologic Cancer Society (IGCS 2024).<\/p>\n<p>The principal investigator of the study, Professor <span class=\"xn-person\">Wu Xiaohua<\/span> from the Fudan University-affiliated Cancer Hospital, presented the results in an oral report, sharing these remarkable outcomes with global experts in gynecological oncology. Concurrently, the findings of the COMPASSION-16 study have been published in the medical journal The Lancet. This also highlights the study&#8217;s pivotal role in advancing the frontiers of international clinical cancer research and its potential role in cervical treatment options.<\/p>\n<p>The COMPASSION-16 study shows that the cadonilimab regimen, with or without bevacizumab, demonstrates promising efficacy in treating persistent, recurrent, or metastatic cervical cancer, addressing a critical unmet need for patients without access to bevacizumab. Additionally, cadonilimab offers significant benefits for all patients, regardless of PD-L1 expression status. This study highlights the clinical value and commercialization potential of cadonilimab to advance standard treatment for advanced cervical cancer.<\/p>\n<p>The primary endpoints of the COMPASSION-16 study were progression-free survival (PFS) and overall survival (OS) assessed by independent central imaging review (BICR) based on RECIST v1.1 criteria. A total of 445 patients were enrolled in the COMPASSION-16 study, with 27.9% of patients in the cadonilimab combined with chemotherapy \u00b1 bevacizumab treatment group having a CPS &lt; 1, compared to 24.2% in the control group.<\/p>\n<p>The study results indicate that the cadonilimab regimen significantly prolonged survival in the overall population, substantially decreasing the risk of disease progression and the risk of death.<\/p>\n<ul type=\"disc\">\n<li>In the intention-to-treat (ITT) population, the median overall survival (OS) for the cadonilimab regimen has not yet been reached, while the control group exhibited a median OS of 22.8 months (the hazard ratio [HR] 0.64, P=0.0011). The 12-month OS rates were 83.1% for the cadonilimab group compared to 73.7% for the control group, and the 24-month OS rates were 62.6% and 48.4%, respectively.<\/li>\n<li>In the ITT population, the median progression-free survival (PFS) for the cadonilimab regimen was 12.7 months, compared to 8.1 months in the control group (HR 0.62, P&lt;0.0001). The 12-month PFS rates were 51.1% and 35% , respectively. As the follow-up time extended (as of <span class=\"xn-chron\">April 30, 2024<\/span>), the benefits of the cadonilimab regimen became increasingly evident, with updated median PFS rates of 13.3 months and 8.2 months (HR 0.62).<\/li>\n<\/ul>\n<p>Regardless of whether it is combined with bevacizumab, the cadonilimab regimen shows a significant improvement in overall survival (OS).<\/p>\n<ul type=\"disc\">\n<li>In the absence of bevacizumab, the cadonilimab regimen is associated with a 50% reduction in the risk of death compared to the control group (OS HR 0.5), thereby effectively addressing the clinical need for patients who are ineligible for bevacizumab.<\/li>\n<\/ul>\n<p>Regardless of PD-L1 expression levels, cadonilimab regimen significantly reduces the risk across the entire patient population.<\/p>\n<ul type=\"disc\">\n<li>In the CPS &lt; 1 cohort, the\u00a0cadonilimab regimen was associated with a 23% reduction in the risk of death (OS HR 0.77). In the CPS \u2265 1 cohort, there was a 31% reduction in the risk of death.(OS HR 0.69). Notably, in the CPS \u2265 10 cohort, the regimen led to a 32% reduction in the risk of death (OS HR 0.68).<\/li>\n<\/ul>\n<p>The cadonilimab regimen exhibits a high and sustained antitumor response.<\/p>\n<ul type=\"disc\">\n<li>The objective response rate (ORR) for the cadonilimab group was 82.9%, compared to 68.6% in the control group. The complete response (CR) rates were 35.6% and 22.9%, respectively. The median duration of response (DOR) was 13.2 months in the cadonilimab group, compared to 8.2 months in the control group.<\/li>\n<\/ul>\n<p>The combination of cadonilimab with chemotherapy \u00b1 bevacizumab has a manageable safety profile, with no new safety signals identified.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>HONG KONG, Oct. 16, 2024 \/PRNewswire\/ &#8212; Akeso Biopharma (9926.HK)\u00a0 (&#8221; Akeso&#8221;, the &#8220;Company&#8221; ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16\/AK104-303). This study evaluated the efficacy of its independently developed PD-1\/CTLA-4 bispecific antibody, \u5f00\u5766\u5c3c\u00ae (cadonilimab), in combination with or without platinum-based chemotherapy and [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60595","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer\" \/>\n<meta property=\"og:description\" content=\"HONG KONG, Oct. 16, 2024 \/PRNewswire\/ &#8212; Akeso Biopharma (9926.HK)\u00a0 (&#8221; Akeso&#8221;, the &#8220;Company&#8221; ) announced positive result\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-16T12:04:45+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer\",\"datePublished\":\"2024-10-16T12:04:45+00:00\",\"dateModified\":\"2024-10-16T12:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/\"},\"wordCount\":657,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/\",\"name\":\"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-16T12:04:45+00:00\",\"dateModified\":\"2024-10-16T12:04:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/","og_locale":"en_US","og_type":"article","og_title":"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer","og_description":"HONG KONG, Oct. 16, 2024 \/PRNewswire\/ &#8212; Akeso Biopharma (9926.HK)\u00a0 (&#8221; Akeso&#8221;, the &#8220;Company&#8221; ) announced positive result","og_url":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-16T12:04:45+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer","datePublished":"2024-10-16T12:04:45+00:00","dateModified":"2024-10-16T12:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/"},"wordCount":657,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/","url":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/","name":"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-16T12:04:45+00:00","dateModified":"2024-10-16T12:04:45+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/igcs-late-breaking-abstract-and-the-lancet-akeso-published-positive-pfs-and-os-results-from-phase-3-first-line-study-of-cadonilimab-in-cervical-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60595"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60595\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}